Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
December 2023
in “
Pharmaceutics
”
Studysummary This review highlights that direct drug delivery to the lungs for treating lung cancer may offer more precise targeting while reducing side effects compared to traditional methods.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The review "Inhaled Medicines for Targeting Non-Small Cell Lung Cancer" explores the advancements in inhaled drug delivery systems for treating NSCLC, emphasizing their potential to enhance drug concentration at the tumor site while minimizing systemic side effects. It discusses various strategies, including nanoparticles, liposomes, and dry powder inhalers, which have shown improved cytotoxicity, bioavailability, and therapeutic efficacy in preclinical and clinical studies. The review underscores the importance of optimizing these delivery systems to improve patient outcomes and highlights the promise of inhaled therapies as a targeted treatment for NSCLC.
